75
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          There is not yet a commonly accepted, standardized approach in the treatment of juvenile idiopathic uveitis when initial steroid therapy is insufficient. We sought to assess current practice patterns within a large cohort of children with juvenile uveitis.

          Methods

          This is a cross-sectional cohort study of patients with uveitis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRAnet) registry. Clinical information including, demographic information, presenting features, disease complications, and medications were collected. Chi-square and Fisher’s exact tests were used to assess for associations between medications and clinical characteristics.

          Results

          Ninety-two children with idiopathic and 656 with juvenile idiopathic arthritis (JIA)-associated uveitis were identified. Indication (arthritis or uveitis) for medication use was not available for JIA patients; therefore, detailed analysis was limited to children with idiopathic uveitis. In this group, 94 % had received systemic steroids. Methotrexate (MTX) was used in 76 % of patients, with oral and subcutaneous forms given at similar rates. In multivariable analysis, non-Caucasians were more likely to be treated initially with subcutaneous MTX ( P = 0.003). Of the 53 % of patients treated with a biologic DMARD, all received a tumor necrosis factor (TNF) inhibitor. TNF inhibitor use was associated with a higher frequency of cataracts (52 % vs 21 %; P = 0.001) and antinuclear antibody positivity (49 % vs 29 %; P = 0.04), although overall complication rates were not higher in these patients.

          Conclusion

          Among idiopathic uveitis patients enrolled in the CARRAnet registry, MTX was the most commonly used DMARD, with subcutaneous and oral forms equally favored. Patients who received a TNF inhibitor were more likely to be ANA positive and have cataracts.

          Electronic supplementary material

          The online version of this article (doi:10.1186/s12969-016-0069-5) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references48

          • Record: found
          • Abstract: not found
          • Book: not found

          Applied Logistic Regression

            • Record: found
            • Abstract: found
            • Article: not found

            Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines.

            To analyse the prevalence and complications of uveitis and their predictors in a large cohort of patients with juvenile idiopathic arthritis (JIA). Data of 3271 JIA patients as classified by International League of Associations for Rheumatology (ILAR) criteria included in a national database during 1 yr were analysed. Uveitis prevalence was 12% of all JIA patients. The most frequent were oligoarthritis extended (25%) and persistent (16%). JIA patients with uveitis were significantly younger at onset of arthritis (3.8 vs 7.0 yrs) or ANA-positive (86% vs 42%) than the patients without uveitis. Predictors of uveitis included age at onset (P= 0.03) and ANA-positivity (P< 0.01) besides the presence of a certain JIA subgroup (P= 0.04). Uveitis was clinically silent in 75% of the oligoarthritis but in none of the enthesitis-related arthritis patients. The median onset of uveitis was 5.5 months after arthritis manifestation. In 73%, 77% and 90%, uveitis developed within 1, 2 and 4 yrs after arthritis, respectively. Anterior uveitis was the most common anatomic type of uveitis (83%). Uveitis complications at mean follow-up of 5.6 yrs were common (56%), and predictors for complications included presence of complications at first visit (P< 0.001) and uveitis manifestation before arthritis (P= 0.001), but not ANA positivity. The JIA subgroups markedly differ with respect to the prevalence and course of associated uveitis. Ophthalmological screening should be initiated early after arthritis onset and the intervals be related to the JIA subgroup. A modification of the current screening guidelines is suggested.
              • Record: found
              • Abstract: found
              • Article: not found

              Ocular complications of pediatric uveitis.

              To determine the cumulative proportion and the visual significance of ocular complications of pediatric uveitis. Cohort study. Patients with onset of endogenous or infectious uveitis before or at age 16 years. Retrospective review of existing records at a university-based uveitis clinic. Type and prevalence of complications related to uveitis, time to development of complications, and vision loss after initial diagnosis. There were 148 patients, 71 males and 77 females, with a mean age of 10.4+/-4.9 years (median, 10.3 years) for an estimated prevalence of pediatric uveitis of 13.8%. Noninfectious uveitis was present in 112 patients (75.7%); 105 (71%) patients had bilateral disease. Anterior uveitis accounted for 30.4%, intermediate uveitis for 27.7%, posterior uveitis for 23.7%, and panuveitis for 18.2% of patients. Patients were followed for a mean of 71.7 months (range, 0 months-44 years) after diagnosis. Approximately 34% of all patients had 1 or more complications at the time of first diagnosis of uveitis by an ophthalmologist, increasing to 61.6% by 3 months, 69.4% by 6 months, 75.2% by 1 year, and 86.3% by 3 years after diagnosis. There were a total of 617 complications of all types. Anterior and intermediate uveitis had a higher risk of band keratopathy (P = 0.005). Posterior and intermediate uveitis had a lower risk of cataract (P = 0.009) or posterior synechiae (P<0.001). Intermediate uveitis had a higher risk of cystoid macular edema compared with anterior or posterior uveitis (P = 0.002). The cumulative percentages (standard error) of patients with first loss to 20/200 or worse after diagnosis in the affected eyes of unilateral cases or in either eye of the bilateral cases were: 31.3% (3.9) at 1 month; 40.5% (4.1) at 6 months; 56.0% (4.3) at 24 months; and 69.6% (4.5) at 60 months. Fifty-four patients (48.2%) received systemic antiinflammatory or immunomodulatory therapy. Sixty-eight patients (45.9%) had ocular surgery, and 38 of these had ocular surgery in both eyes. Childhood uveitis is significant for numerous complications, many of which are vision threatening. Complications increase with duration of disease.

                Author and article information

                Contributors
                617-355-6117 , Lauren.Henderson@childrens.harvard.edu
                david.zurakowski@childrens.harvard.edu
                sangele@emory.edu
                Alasky@lhs.org
                egla.rabinovich@duke.edu
                Mindy.Lo@childrens.harvard.edu
                Journal
                Pediatr Rheumatol Online J
                Pediatr Rheumatol Online J
                Pediatric Rheumatology Online Journal
                BioMed Central (London )
                1546-0096
                16 February 2016
                16 February 2016
                2016
                : 14
                : 9
                Affiliations
                [ ]Division of Immunology, Boston Children’s Hospital, Boston, MA and Department of Pediatrics, Harvard Medical School, 1 Blackfan Circle, Karp Building, 10th Floor, Boston, MA 02115 USA
                [ ]Departments of Anesthesia and Surgery, Boston Children’s Hospital and Harvard Medical School, Boston, MA USA
                [ ]Department of Pediatrics and Ophthalmology, Emory University School of Medicine, Atlanta, GA USA
                [ ]Department of Pediatric Rheumatology, Randall Children’s Hospital at Legacy Emanuel, Portland, OR USA
                [ ]Division of Rheumatology, Department of Pediatrics, Duke Children’s, Durham, NC USA
                Article
                69
                10.1186/s12969-016-0069-5
                4755024
                26879972
                d51391bb-08cf-4c0e-95bb-ff445da09d78
                © Henderson et al. 2016

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 14 July 2015
                : 4 February 2016
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100000053, National Eye Institute (US);
                Award ID: K23EY021760
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100006260, Rheumatology Research Foundation (US);
                Award ID: Scientist Development Award
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100000060, National Institute of Allergy and Infectious Diseases (US);
                Award ID: T32AI007512
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/http://dx.doi.org/10.13039/100000069, National Institute of Arthritis and Musculoskeletal and Skin Diseases (US);
                Award ID: RC2AR058934
                Funded by: FundRef http://dx.doi.org/http://dx.doi.org/10.13039/100000980, Arthritis Foundation (US);
                Funded by: Friends of CARRA
                Funded by: FundRef http://dx.doi.org/http://dx.doi.org/10.13039/100006513, Duke Clinical Research Institute (US);
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2016

                Pediatrics
                uveitis,juvenile idiopathic arthritis (jia),idiopathic uveitis,dmard,infliximab,adalimumab,methotrexate

                Comments

                Comment on this article

                Related Documents Log